110 related articles for article (PubMed ID: 16751688)
1. [Bone and bone related biochemical examinations. Hormone and hormone related substances. The measurement of circulating fibroblast growth factor 23 (FGF-23)].
Kobayashi K; Imanishi Y
Clin Calcium; 2006 Jun; 16(6):935-39. PubMed ID: 16751688
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
3. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
4. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.
Durham BH; Joseph F; Bailey LM; Fraser WD
Ann Clin Biochem; 2007 Sep; 44(Pt 5):463-6. PubMed ID: 17761032
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
7. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
8. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
10. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
[TBL] [Abstract][Full Text] [Related]
11. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
12. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
13. Intact fibroblast growth factor 23 and fragments in plasma from Gambian children.
Braithwaite V; Bruggraber SF; Prentice A
Osteoporos Int; 2013 Mar; 24(3):1121-4. PubMed ID: 22648001
[TBL] [Abstract][Full Text] [Related]
14. [Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].
Ozono K
Clin Calcium; 2010 Jun; 20(6):896-903. PubMed ID: 20513948
[TBL] [Abstract][Full Text] [Related]
15. [Clinical aspect of recent progress in phosphate metabolism. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23)].
Endo I
Clin Calcium; 2009 Jun; 19(6):815-20. PubMed ID: 19483276
[TBL] [Abstract][Full Text] [Related]
16. Determination of fibroblast growth factor 23.
Heijboer AC; Levitus M; Vervloet MG; Lips P; ter Wee PM; Dijstelbloem HM; Blankenstein MA
Ann Clin Biochem; 2009 Jul; 46(Pt 4):338-40. PubMed ID: 19564163
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two assays for fibroblast growth factor (FGF)-23.
Ito N; Fukumoto S; Takeuchi Y; Yasuda T; Hasegawa Y; Takemoto F; Tajima T; Dobashi K; Yamazaki Y; Yamashita T; Fujita T
J Bone Miner Metab; 2005; 23(6):435-40. PubMed ID: 16261449
[TBL] [Abstract][Full Text] [Related]
18. C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.
Bharati J; Bhatia D; Khandelwal P; Gupta N; Sinha A; Khadgawat R; Hari P; Bagga A
Indian J Pediatr; 2019 Jun; 86(6):555-557. PubMed ID: 30835073
[TBL] [Abstract][Full Text] [Related]
19. Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system.
Kato H; Hidaka N; Koga M; Ogawa N; Takahashi S; Miyazaki H; Nangaku M; Makita N; Ito N
J Bone Miner Metab; 2022 Jan; 40(1):101-108. PubMed ID: 34351500
[TBL] [Abstract][Full Text] [Related]
20. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
